search
Back to results

Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus

Primary Purpose

Diabetes Insipidus, Nephrogenic

Status
Completed
Phase
Locations
Study Type
Observational
Intervention
chlorothiazide
Sponsored by
National Center for Research Resources (NCRR)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an observational trial for Diabetes Insipidus, Nephrogenic focused on measuring diabetes insipidus, endocrine disorders, rare disease

Eligibility Criteria

6 Months - 70 Years (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

PROTOCOL ENTRY CRITERIA: Known or suspected congenital nephrogenic diabetes insipidus Clinically and genetically unaffected relatives entered as controls --Patient Characteristics-- Age: 6 months to 70 years

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    October 18, 1999
    Last Updated
    June 23, 2005
    Sponsor
    National Center for Research Resources (NCRR)
    Collaborators
    Northwestern University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00004360
    Brief Title
    Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus
    Study Type
    Observational

    2. Study Status

    Record Verification Date
    December 1999
    Overall Recruitment Status
    Completed
    Study Start Date
    September 1995 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    National Center for Research Resources (NCRR)
    Collaborators
    Northwestern University

    4. Oversight

    5. Study Description

    Brief Summary
    OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
    Detailed Description
    PROTOCOL OUTLINE: A detailed family history is obtained from all participants. Whenever possible, standard growth curves of affected children are obtained. Participants then undergo clinical studies of antidiuretic function. A standard fluid deprivation-vasopressin challenge is performed with timed measurements of osmolality, electrolytes, creatinine, and vasopressin. The next day, blood pressure, plasma cyclic AMP, GMP, von Willebrand Factor, Factor VIII, and urine osmolality are measured during a water load desamino-D-arginine vasopressin (dDAVP) infusion test. Participants with a confirmed diagnosis of congenital diabetes insipidus are then treated with chlorothiazide. Daily urine volume and osmolality are determined before and after therapy. Sodium and fluid are not restricted. For each family, the entire vasopressin V2 gene of at least 1 affected male, and where possible at least 1 obligate carrier and 1 unaffected brother of a patient is sequenced. In addition, a detailed Xq28 haplotype analysis is done to identify the origin of de novo mutations. If no mutation is found and the disorder is not transmitted in an X-linked mode, both alleles of the gene that codes for aquaporin-II are also sequenced. DNA is collected by mail from as many kindred as possible who do not participate in the clinical studies.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetes Insipidus, Nephrogenic
    Keywords
    diabetes insipidus, endocrine disorders, rare disease

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    chlorothiazide

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    6 Months
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    PROTOCOL ENTRY CRITERIA: Known or suspected congenital nephrogenic diabetes insipidus Clinically and genetically unaffected relatives entered as controls --Patient Characteristics-- Age: 6 months to 70 years
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Gary L. Robertson
    Organizational Affiliation
    Northwestern University
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    8037205
    Citation
    Bichet DG, Birnbaumer M, Lonergan M, Arthus MF, Rosenthal W, Goodyer P, Nivet H, Benoit S, Giampietro P, Simonetti S, et al. Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. Am J Hum Genet. 1994 Aug;55(2):278-86.
    Results Reference
    background
    PubMed Identifier
    9369448
    Citation
    Sadeghi H, Robertson GL, Bichet DG, Innamorati G, Birnbaumer M. Biochemical basis of partial nephrogenic diabetes insipidus phenotypes. Mol Endocrinol. 1997 Nov;11(12):1806-13. doi: 10.1210/mend.11.12.0017.
    Results Reference
    background
    Citation
    Robertson GL, McLeod JF, Zerbe RL, et al.: Vasopressin function in heritable forms of diabetes insipidus. In: Gross P, Richter D, Robertson GL, eds.: Vasopressin: IV International Vasopressin Conference, May 23-27, 1993, Berlin Germany. Paris: John Libbey Eurotext, 1993, pp 493-503.
    Results Reference
    background
    PubMed Identifier
    7987330
    Citation
    Wenkert D, Merendino JJ Jr, Shenker A, Thambi N, Robertson GL, Moses AM, Spiegel AM. Novel mutations in the V2 vasopressin receptor gene of patients with X-linked nephrogenic diabetes insipidus. Hum Mol Genet. 1994 Aug;3(8):1429-30. doi: 10.1093/hmg/3.8.1429. No abstract available.
    Results Reference
    background

    Learn more about this trial

    Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus

    We'll reach out to this number within 24 hrs